TY - JOUR
T1 - Survival and prognostic factors in patients with rectal squamous cell carcinoma
AU - Kommalapati, Anuhya
AU - Tella, Sri Harsha
AU - Yadav, Siddhartha
AU - Goyal, Gaurav
AU - Hallemeier, Christopher
AU - Durgin, Lori
AU - Jin, Zhaohui
AU - Mahipal, Amit
N1 - Funding Information:
The work is accepted for poster presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 2019.
PY - 2020/6
Y1 - 2020/6
N2 - Background: Squamous cell carcinoma (SCC) of the rectum is a rare form of gastrointestinal malignancy. The current knowledge on the natural history is primarily derived from case series. Methods: Using the National Cancer Data Base (NCDB), we determined the prognostic factors and overall survival (OS) outcomes of rectal SCC reported to NCDB between 2004 and 2015. Kaplan-Meier method and log-rank test were used to perform OS analysis. Propensity matched analysis was undertaken to compare the OS outcomes between rectal and anal SCC. Results: Of the 3405 cases included in our analysis, 67% were female. Median age at diagnosis was 61 years and did not differ by sex. In stages I-III, patients who received definitive chemoradiation only (108 months) had a better median OS as compared to surgery alone (76 months) (p = 0.012). On multivariate analysis, age <60 years, female sex, and receipt of chemoradiation with or without surgery were independent predictors of better OS in stage I-III disease. Administration of chemoradiation was associated with better OS in stage IV disease. On propensity matched analysis comparing outcomes to anal SCC, OS of rectal SCC was inferior (79 months) to anal SCC (113 months) (p < 0.001), no such difference in OS was noted in the cohorts that received surgery plus post-surgical chemoradiation (p = 0.12). Conclusion: Outcomes of rectal SCC were dependent upon age, sex, comorbidity score, and therapy received. Chemoradiation alone or in combination with surgery was associated with a better median OS in patients with stages I-III.
AB - Background: Squamous cell carcinoma (SCC) of the rectum is a rare form of gastrointestinal malignancy. The current knowledge on the natural history is primarily derived from case series. Methods: Using the National Cancer Data Base (NCDB), we determined the prognostic factors and overall survival (OS) outcomes of rectal SCC reported to NCDB between 2004 and 2015. Kaplan-Meier method and log-rank test were used to perform OS analysis. Propensity matched analysis was undertaken to compare the OS outcomes between rectal and anal SCC. Results: Of the 3405 cases included in our analysis, 67% were female. Median age at diagnosis was 61 years and did not differ by sex. In stages I-III, patients who received definitive chemoradiation only (108 months) had a better median OS as compared to surgery alone (76 months) (p = 0.012). On multivariate analysis, age <60 years, female sex, and receipt of chemoradiation with or without surgery were independent predictors of better OS in stage I-III disease. Administration of chemoradiation was associated with better OS in stage IV disease. On propensity matched analysis comparing outcomes to anal SCC, OS of rectal SCC was inferior (79 months) to anal SCC (113 months) (p < 0.001), no such difference in OS was noted in the cohorts that received surgery plus post-surgical chemoradiation (p = 0.12). Conclusion: Outcomes of rectal SCC were dependent upon age, sex, comorbidity score, and therapy received. Chemoradiation alone or in combination with surgery was associated with a better median OS in patients with stages I-III.
KW - Adenocarcinoma
KW - NCDB
KW - Overall survival
KW - Rectal carcinoma
KW - Squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85082409859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082409859&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2020.02.039
DO - 10.1016/j.ejso.2020.02.039
M3 - Article
C2 - 32201124
AN - SCOPUS:85082409859
SN - 0748-7983
VL - 46
SP - 1111
EP - 1117
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 6
ER -